I am a life sciences executive and entrepreneur with functional backgrounds in corporate and business development and law and international experience. My passion is start-up and emerging companies, having held senior and leadership positions in public and private biotech, pharmaceutical, medtech and other companies, and advised academic teams regarding commercializing their research.
After receiving A.B. and J.D. degrees from Harvard, I practiced securities and transactional law in the New York City and London offices of law firm Lord Day & Lord, Barrett Smith. I then served as General Counsel of Consolidated Press (U.S.), the North American holding company for the late Australian billionaire, Kerry Packer, in Livonia, Michigan. Next, I held various legal management posts at the ICN Pharmaceuticals group of companies in Costa Mesa, California, including VP, General Counsel and Secretary of Viratek, the R&D entity of the group that developed the antiviral VIRAZOLE® and engaged in antisense oligonucleotide research. I then joined Guilford Pharmaceuticals, a public biotech company in Baltimore commercializing GLIADEL® wafer for glioblastoma multiforme and developing the propofol pro-drug that became LUSEDRA® and small molecules for Parkinson’s disease and other neurodegenerative diseases. I began as VP, General Counsel & Secretary, then moved to the business side, as SVP Corporate and Commercial Development. Next, I was CEO of Faust Pharmaceuticals, S.A., a venture-backed B-round stage company in Strasbourg, France, with a re-purposed compound in Phase II for Parkinson’s patients, a re-positioned molecule for Duchenne muscular dystrophy and a GPCR drug discovery platform. I was also on the Board of Directors of Arbios Systems, a Bulletin Board-listed Cedars Sinai spin-out with an ex vivo liver dialysis device in clinical development.
Since repatriating to the U.S., I have been engaged in start-up and advisory activities, including stints as President of NexGen Medical Systems, a private medtech seeking to commercialize a novel mechanical thrombectomy device for Deep Vein Thrombosis and stroke and a state-of-the-art neurocatheter, President and CEO of Eqalix, Inc., a regenerative medicine device company based in Reston, VA developing the first plant-based skin substitute wound dressing, to replace products made from humans and animals in the multibillion dollar global wound care market, and member of the Johns Hopkins Alliance, an industry-faculty advisory board. I also co-founded Lemma Pharmaceuticals, Inc., a San Diego start up that licensed technology from UCSD regarding liposomal encapsulation of staurosporine and its analogs for brain and other cancers.
Interests beyond work and my family include tennis, hiking, ballet and wrestling with the ontological implications of quantum mechanics.